Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Curent Deferred Tax Liability: 2015-2019

Historic Curent Deferred Tax Liability for Assembly Biosciences (ASMB) over the last 4 years, with Mar 2019 value amounting to $3.3 million.

  • Assembly Biosciences' Curent Deferred Tax Liability rose 52.26% to $3.3 million in Q1 2019 from the same period last year, while for Mar 2019 it was $3.3 million, marking a year-over-year increase of 52.26%. This contributed to the annual value of $3.3 million for FY2018, which is 52.25% up from last year.
  • Per Assembly Biosciences' latest filing, its Curent Deferred Tax Liability stood at $3.3 million for Q1 2019, which was down 0.00% from $3.3 million recorded in Q4 2018.
  • Assembly Biosciences' 5-year Curent Deferred Tax Liability high stood at $11.6 million for Q1 2015, and its period low was $2.1 million during Q3 2018.
  • In the last 3 years, Assembly Biosciences' Curent Deferred Tax Liability had a median value of $3.3 million in 2019 and averaged $5.4 million.
  • As far as peak fluctuations go, Assembly Biosciences' Curent Deferred Tax Liability tumbled by 81.13% in 2018, and later skyrocketed by 52.26% in 2019.
  • Assembly Biosciences' Curent Deferred Tax Liability (Quarterly) stood at $11.6 million in 2015, then declined by 4.14% to $11.1 million in 2016, then crashed by 80.79% to $2.1 million in 2017, then soared by 52.25% to $3.3 million in 2018, then skyrocketed by 52.26% to $3.3 million in 2019.
  • Its last three reported values are $3.3 million in Q1 2019, $3.3 million for Q4 2018, and $2.1 million during Q3 2018.